This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

9 Meters Biopharma Dirección

Dirección controles de criterios 0/4

We currently do not have sufficient information about the CEO.

Información clave

Bethany Sensenig

Chief Executive Officer (CEO)

US$1.3m

Compensación total

Porcentaje del salario del CEO	35.7%
Permanencia del CEO	1.5yrs
Participación del CEO	0.2%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	2.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bethany Sensenig en comparación con los beneficios de 9 Meters Biopharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$1m	US$457k	-US$44m

Compensación vs. Mercado: Bethany's total compensation ($USD1.28M) is above average for companies of similar size in the German market ($USD457.20K).

Compensación vs. Ingresos: Insufficient data to compare Bethany's compensation with company performance.

CEO

Bethany Sensenig (47 yo)

1.5yrs

Permanencia

US$1,279,586

Compensación

Ms. Bethany Sensenig MBA, CMA, serves as Interim Chief Executive Officer of 9 Meters Biopharma, Inc. since May 30, 2023. She serves as a Chief Financial Officer at 9 Meters Biopharma, Inc. since January 15...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Lorin Johnson	Independent Director	5.5yrs	US$84.70k	0.057% $ 4.5k
Mark Sirgo	Independent Chairman	3.3yrs	US$119.70k	0.57% $ 46.0k
Mark Pimentel	Member of Scientific Advisory Board	2.9yrs	sin datos	sin datos
Michael Rice	Independent Director	2.4yrs	US$78.45k	0.027% $ 2.2k
Michael Constantino	Independent Director	3.1yrs	US$82.20k	0.048% $ 3.9k
Z. Falchuk	Member of Scientific Advisory Board	2.9yrs	sin datos	sin datos
Maureen Leonard	Member of Scientific Advisory Board	2.9yrs	sin datos	sin datos
Russel Cohen	Member of Scientific Advisory Board	2.9yrs	sin datos	sin datos
Benjamin Lebwohl	Member of Scientific Advisory Board	2.9yrs	sin datos	sin datos
Charles Randall	Member of Scientific Advisory Board	2.9yrs	sin datos	sin datos
Samantha Ventimiglia	Independent Director	1.8yrs	US$67.20k	0.027% $ 2.2k

2.9yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: 2Q3A's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

This company listing is no longer active

9 Meters Biopharma Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President

High number of new and inexperienced directors

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought €50k worth of stock

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought €50k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Independent Chairman recently bought €84k worth of stock

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

New 90-day high: €1.86

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: €1.22

New 90-day high: €1.19

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

New 90-day high: €0.85

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

Independent Chairman recently bought €81k worth of stock

New 90-day high - €0.74

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad